Abstract
Background
GOLD 2013 guidelines classify patients with COPD in terms of risk and symptoms (A: low risk, less symptoms; B: low risk, more symptoms; C: high risk, less symptoms and D: high risk, more symptoms). Long-acting muscarinic antagonists such as aclidinium are now recommended as first-choice option for Group B–D patients and as an alternative choice for Group A patients.
Aim
To assess the efficacy of aclidinium 400 µg twice daily (BID) in patients with COPD according to GOLD 2013 criteria.
Methods
Data were pooled from the placebo and aclidinium 400 µg BID arms of three, 6-month, placebo-controlled studies evaluating aclidinium mono- or combination-therapy in patients with moderate-to-severe COPD, stratified to GOLD group using SGRQ total score (surrogate for CAT).
Results
In total, 1787 patients were included (mean±SD: age 63.3±8.4 years, 63.0% male, 54.25±13.13 % predicted). At baseline, mean FEV1 ranged from 1.103 L (Group C) to 1.695 L (Group A); 7.9% of patients were Group A, 48.4% Group B, 3.1% Group C and 41.4% Group D. At Week 24, aclidinium was associated with improved trough and peak FEV1 in all GOLD groups compared with placebo (see Table). Numerically the largest differences in trough FEV1 between aclidinium and placebo were in Group A.
Conclusions
Aclidinium improved lung function in all patients regardless of GOLD group; the numerically largest improvements were in Group A.
- © 2014 ERS